Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for August 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
More HIV-Exposed Uninfected Infants Have Group B Strep
MONDAY, Aug. 23 (HealthDay News) -- HIV-exposed uninfected (HEU) infants may be more susceptible to invasive group B streptococcal (GBS) infections in terms of incidence and severity than babies born to HIV-uninfected mothers, according to research published online Aug. 23 in Pediatrics.
HIV Viral Populations in Semen Different Than in Blood
FRIDAY, Aug. 20 (HealthDay News) -- HIV-1 living in the genital tract displays genetic differences from HIV-1 in the bloodstream, suggesting three mechanisms leading to the virus getting into semen, according to a study published online Aug. 19 in PLoS Pathogens.
Proteinuria Prevalent in Injection Drug Users With HIV
FRIDAY, Aug. 13 (HealthDay News) -- Proteinuria is common among injection drug users, especially those who have HIV, according to a study published online Aug. 12 in the Clinical Journal of the American Society of Nephrology.
Industry-Funded Clinical Trials Yield More Positive Outcomes
TUESDAY, Aug. 3 (HealthDay News) -- Drug clinical trials supported by industry are more likely to produce favorable results than trials supported by government or nonprofit/nonfederal organizations, and they are less likely to be published within two years of the study being completed, according to research published in the Aug. 3 issue of the Annals of Internal Medicine.
Copyright © 2010 ScoutNews, LLC. All rights reserved.
|Previous: August 2010 Briefing - Gastroenterology||Next: August 2010 Briefing - Infectious Disease|
Reader comments on this article are listed below. Review our comments policy.